Geron swings to Q3 2026 net profit of $1.35 million from year-earlier loss
Bitget2026/11/04 12:14- Geron swung to third-quarter 2026 net income of $1.35 million from a year-earlier net loss of $18.43 million.
- Product revenue, net rose 27% year over year to $60.11 million, while total costs and operating expenses fell 11% to $54.39 million.
- The Phase 3 IMpactMF trial was discontinued following an independent committee’s assessment that it was unlikely to meet its overall-survival endpoint.
- A targeted European RYTELO launch began, with availability expected in Germany by year-end and France in 2027.
- FY26 product revenue, net guidance remained at $220 million–$240 million’s mid-to-high end; operating expense guidance fell to $220 million–$230 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
